Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
Rhea-AI Summary
Bicara Therapeutics (Nasdaq: BCAX) will report fourth quarter and full year 2025 financial results and provide business updates on March 30, 2026 before market open. A conference call and live webcast will occur at 8:30 a.m. ET, with registration, dial-in PINs, and a 30-day replay available.
Positive
- None.
Negative
- None.
News Market Reaction – BCAX
On the day this news was published, BCAX declined 0.11%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BCAX fell 2.02% while peers TYRA (-3.93%), ANAB (-3.27%), PVLA (-1.03%), RIGL (-0.23%), and TERN (-0.16%) were also down, indicating broader biotech softness.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Inducement option grant | Neutral | +3.5% | Inducement non-qualified stock option for 115,000 shares at $17.59. |
| Feb 26 | Offering closed | Negative | -0.1% | Closing of oversubscribed equity offering and full exercise of underwriters’ option. |
| Feb 24 | Offering priced | Negative | +7.8% | Pricing of $150M public offering of stock and pre-funded warrants. |
| Feb 24 | Offering proposed | Negative | +7.8% | Proposed $150.0M common stock offering with $22.5M underwriter option. |
| Feb 23 | Investor conferences | Positive | +5.9% | Participation in multiple March 2026 investor conferences with webcasts. |
Recent capital-raising and investor-relations events often saw positive price reactions, even around dilutive offerings.
Over recent months, BCAX has focused on financing and investor outreach. In February 2026, it announced a proposed $150.0 million offering and then priced and closed an oversubscribed deal with gross proceeds of about $172.5 million, funding ficerafusp alfa regulatory and commercial plans. An inducement stock option grant on March 2, 2026 and investor conference participation in early March supported engagement. Today’s earnings-date announcement fits this cadence of scheduled corporate updates.
Regulatory & Risk Context
The company has an active Form S-3 shelf registration dated October 3, 2025, which has been used in multiple 424B5 offerings, enabling it to issue securities relatively quickly as demonstrated by recent financings.
Market Pulse Summary
This announcement sets expectations for BCAX’s fourth quarter and full year 2025 results on March 30, 2026 at 8:30 a.m. ET. Investors may contextualize upcoming financials against recent capital raises off an effective shelf and a series of insider option exercises and sales. Key items to watch include cash position, spending on ficerafusp alfa, and any guidance that complements prior financing and conference disclosures.
AI-generated analysis. Not financial advice.
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day.
Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (“TGF-β”). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types.
Contacts:
Investors
Rachel Frank
IR@bicara.com
Media
Amanda Lazaro
Amanda@1abmedia.com
FAQ
When will Bicara Therapeutics (BCAX) report Q4 and full year 2025 results?
How can investors join the Bicara (BCAX) March 30, 2026 earnings call at 8:30 a.m. ET?
Will Bicara Therapeutics (BCAX) provide a webcast and replay for the March 30, 2026 presentation?
What time is Bicara (BCAX) scheduled to discuss business updates on March 30, 2026?
Where can I find the dial-in details and PIN for Bicara Therapeutics (BCAX) March 30, 2026 call?
